Trial Profile
Study to evaluate the safety and efficacy of BioLinx polymer- Versus Phosphorylcholine polymer-Zotarolimus-eluting stents in patient who had undergone Percutaneous Coronary Intervention
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Sep 2018
Price :
$35
*
At a glance
- Drugs Zotarolimus (Primary)
- Indications Coronary artery restenosis
- Focus Therapeutic Use
- 19 Sep 2018 New trial record
- 29 Aug 2018 Results presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology